BNTX:NASDAQ
BioNTech SE - ADR
$96.35
arrow_upward
+0.65%(+0.62) 1D
Oct 7, 1:11:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$95.17
High
$97.46
Low
$93.92
Mkt. cap
24.23B
Avg. vol.
1.01M
Volume
364.00K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.55
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$95.17
High
$97.46
Low
$93.92
Mkt. cap
24.23B
Avg. vol.
1.01M
Volume
364.00K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.55
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
GuruFocus
·
1 hour ago
BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11
Investing.com Nigeria
·
13 hours ago
Form 4 BioNTech SE For: 7 October By Investing.com
AD HOC NEWS
·
19 hours ago
BioNTech stock fell 1.96 percent despite a Buy consensus
Yahoo Finance
·
1 day ago
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR